Navigation Links
Cyberonics Names Bryan D. Olin, Ph.D. Vice President, Quality
Date:5/18/2009

HOUSTON, May 18 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that Bryan D. Olin, Ph.D., joined Cyberonics as Vice President, Quality, effective on May 18, 2009. Dr. Olin will lead all of the company's quality programs.

Dr. Olin joins Cyberonics from Zeltiq Aesthetics, an aesthetics device firm in California, where he served as Senior Director, Quality Assurance, since October 2007. Prior to Zeltiq, Dr. Olin was employed as Executive Director, Failure Analysis, Product Quality Services and Product Safety with Cordis Corporation, a Johnson & Johnson company. Dr. Olin spent five years with another Johnson & Johnson company, LifeScan, as the Manager, Statistical Engineering; Senior Program Manager, QA; Director, Complaint Handling and QA Laboratories; and Director, Clinical Biometrics and Complaint Management. Dr. Olin began his business career as a Statistician for Procter & Gamble, providing statistical support to a diverse set of internal clients in R&D and manufacturing.

"Bryan brings substantial expertise in quality management that will be helpful in all aspects of our regulated business, including manufacturing and product development," said Dan Moore, Cyberonics' President and Chief Executive Officer. "He has extensive experience with regulatory inspections and submissions, complaint handling, CAPAs and clinical study design. We are pleased to have Bryan joining our team to lead the global quality system and programs."

Dr. Olin received a B.S. in Mathematics from the University of Kansas. He was awarded a Masters of Science and his Ph.D. in Statistics from Iowa State University. Dr. Olin served as an Adjunct Assistant Professor of Industrial Pharmacy at the University of Cincinnati for three years.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (NASDAQ: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.

Contact information

    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd.
    Houston, TX 77058
    Main:  (281) 228-7262
    Fax:  (281) 218-9332
    ir@cyberonics.com


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
2. Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter
3. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results
4. Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development
5. Cyberonics to Present at Piper Jaffray 20th Annual Health Care Conference
6. Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Second Quarter
7. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
8. Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS
9. Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike
10. Cyberonics to Present at UBS Global Life Sciences Conference
11. Cyberonics to Present at Canaccord Adams 28th Annual Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... CA (PRWEB) , ... May ... ... lectures and hands-on exercises, the Wharton Seminars for Business Journalists , ... better understanding of key business and economic issues.  This one-day program at ...
(Date:5/5/2016)... , ... May 05, 2016 , ... LELO ... self-love. Every day, LELO fans reach out via email, social media and on the ... upcoming up: “Is the way I masturbate ‘normal’ or ‘correct’?” , While some methods ...
(Date:5/5/2016)... Indianapolis, IN (PRWEB) , ... May 05, 2016 ... ... employee benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition ... & Smoak Benefits has a dedicated team of compliance, wellness, human resources, and ...
(Date:5/5/2016)... Bremerton, WA (PRWEB) , ... May 05, 2016 , ... ... program serving the families of Bremerton, Port Orchard and communities west of Seattle. The ... Lowery, a 12 year local girl who died suddenly due to complications from the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... grants the most heartfelt wishes of these children. The wishes provide hope ... President and CEO of Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Valeritas Holdings, Inc. (OTCQB: VLRX) ... offering (APO). This was accomplished via a reverse merger ... a private placement of approximately 5 million shares of ... Under the terms of the reverse merger, which ... will trade on the OTC Markets under the symbol ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute lymphocytic Leukemia Market ... to their offering.       (Logo: ... Acute Lymphocytic Leukemia Market and Competitive Landscape ... Lymphocytic Leukemia pipeline products, Acute Lymphocytic Leukemia ...
(Date:5/3/2016)... 3, 2016  As a teenager, an active and ... which damaged his heart. He continued enjoying sports and ... 2013, Shepherd,s heart was giving out and he was ... 20, 2013, the Mesa, Arizona ... Like a heart transplant, the SynCardia TAH-t is the ...
Breaking Medicine Technology: